ArticleFrontiers in medicine2025
Optimal Res-UNET architecture with deep supervision for tumor segmentation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep Learning Based on DeepLabv3+ for Automated Identification, Segmentation, and Quantification of Fungi in Clinical Fluorescence Microscopy Images.Mycopathologia · 2026Article
- Development of an Artificial Intelligence-Driven Three-Dimensional Reconstruction Model of Renal Vasculature for Surgical Planning in Robot-Assisted Partial Nephrectomy.The international journal of medical robotics + computer assisted surgery : MRCAS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain tumor segmentation is critical in medical imaging due to its significance in accurate diagnosis and treatment planning. Deep learning (DL) methods, particularly the U-Net architecture, have demonstrated considerable promise. However, optimizing U-Net variants to enhance performance and computational efficiency remains challenging. Objective: To develop an optimized Residual U-Net (Res-UNET) architecture enhanced by deep supervision techniques to improve segmentation accuracy of brain tumors on MRI datasets, specifically addressing challenges of conventional segmentation methods. Methods: The study implemented a detailed evaluation of multiple U-Net variations, including basic U-Net, Res-UNet with Autoencoder regularization, and attention-enhanced U-Net architectures. Training was conducted using the BraTS 2018 public MRI dataset. Deep supervision was integrated to improve gradient propagation and segmentation accuracy. The model employed a Dice loss combined with focal loss to handle data imbalance effectively. The proposed network was evaluated using extensive ablation studies, examining the effects of encoder complexity, convolutional filter count, and strategic post-processing. Results: The proposed Res-UNET with deep supervision outperformed other variants, achieving an average Dice score of 0.9498 through five-fold cross-validation. Post-processing strategies improved the robustness of segmentation, particularly enhancing the accuracy of small tumor regions. Comparatively, conventional U-Net architectures yielded lower Dice scores and required significantly longer training times. The study indicates the benefit of integrating deep supervision and residual connections for enhanced model performance. Conclusion: Optimized Res-UNET with deep supervision significantly enhances segmentation accuracy for brain tumors in MRI images, surpassing traditional U-Net models. This model addresses critical issues such as dataset imbalance, lack of annotated data, and computational inefficiencies. Future studies should consider the broader application of optimized U-Net variants across other medical imaging segmentation tasks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.